Vimarsana
Biggest News Aggregation in the World

Page 43 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Boxed Warning Today - Breaking & Trending Today

Study Reveals Foster Children 4x More Likely to Get Psychotropic Drugs Than Non-Foster Children - Vimarsana News

Study Reveals Foster Children 4x More Likely to Get Psychotropic Drugs Than Non-Foster Children

Study Reveals Foster Children 4x More Likely to Get Psychotropic Drugs Than Non-Foster Children

Talvey Gets Accelerated Approval for Myeloma Treatment - Vimarsana News

Talvey Gets Accelerated Approval for Myeloma Treatment

The FDA granted an accelerated approval for Talvey to treat patients with relapsed/refractory multiple myeloma.

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma - Vimarsana News

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...

FDA Grants Accelerated Approval to Talquetamab-tgvs for Patients With Heavily Pretreated Multiple Myeloma - Vimarsana News

FDA Grants Accelerated Approval to Talquetamab-tgvs for Patients With Heavily Pretreated Multiple Myeloma

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance - Vimarsana News

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

– LINZESS EUTRx prescription demand growth increased 9% year-over-year; LINZESS U.S. net sales of $270 million, an increase of 9% year-over-year – – Expands clinical utility of LINZESS with...